Reversal of multidrug resistance by a novel quinoline derivative, MS-209 Wakao SatoNobuyuki FukazawaTakashi Tsuruo Original Article 01 July 1995 Pages: 271 - 277
Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy Hideomi WatanabeAkira HasegawaMasaki Chigira Original Article 01 July 1995 Pages: 278 - 282
Intracellular activation and cytotoxic action of RS-1541 against cultured human tumor cells Toshiro TakatoriTakeshi KoizumiTakashi Tsuruo Original Article 01 July 1995 Pages: 283 - 290
A possible mechanism for the cytotoxicity of a polyacetylenic alcohol, panaxytriol: inhibition of mitochondrial respiration H. MatsunagaT. SaitaM. Katano Original Article 01 July 1995 Pages: 291 - 296
Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol Luka MilasNancy R. HunterLester J. Peters Original Article 01 July 1995 Pages: 297 - 303
A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest E. E. VokesD. J. HarafH. M. Golomb Original Article 01 July 1995 Pages: 304 - 312
Biological disposition of intravenously administered131I-labeled anti-EGF-receptor antibody (RG 83852) in the rat V. K. KhetarpalL. S. Storbeck Original Article 01 July 1995 Pages: 313 - 317
Conversion of mitomycin C to 2,7-diaminomitosene and 10-decarbamoyl 2,7-diaminomitosene in tumour tissue in vivo Linda ChirreyJeffrey CummingsJohn F. Smyth Original Article 01 July 1995 Pages: 318 - 322
Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individuals G. N. RuddJ. A. HartleyR. L. Souhami Original Article 01 July 1995 Pages: 323 - 326
Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells Lidija Beketic-OreskovicMaja Osmak Original Article 01 July 1995 Pages: 327 - 333
No synergistic activity of epirubicin and interferon-α2b in the treatment of hepatocellular carcinoma Carsten BokemeyerBernd KynastHans-Joachim Schmoll Clinical Trial Report 01 July 1995 Pages: 334 - 338
5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer E. BolliS. SaccomannoGLISP (Gruppo Ligure Studio Pancreas) Clinical Trial Report 01 July 1995 Pages: 339 - 342
Vincristine and oral etoposide in refractory multiple myeloma Ram K. GanjooAlan WilliamsJames S. Malpas Clinical Trial Report 01 July 1995 Pages: 343 - 344
The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant butP-glycoprotein-negative and cisplatin-resistant counterparts Winette T. A. van der GraafNanno H. MulderElisabeth G. E. de Vries Short Communication 01 July 1995 Pages: 345 - 348
Hypersensitivity and cross-reactivity to cisplatin and analogues A. A. ShlebakP. I. ClarkJ. A. Green Short Communication 01 July 1995 Pages: 349 - 351
Cerebrospinal fluid concentrations of carboplatin in a patient without blood-brain barrier disruption V. BrunnerP. HouyauP. Canal Letter to the Editors 01 July 1995 Pages: 352 - 353